Our analysis of Vizient, Inc. data shows that acute MI events after TAVR are rare. Revascularization rates similar in post-TAVR AMI patients vs. all-comer AMI. Excited to be presenting results at #ACC24 with sim pub in JACC Journals. Link: tinyurl.com/2t7pt3t8 Harold Dauerman

LATE BREAKING news! #TriClip G4 just FDA Medical Devices approved! Finally both repair and replacement options for our pts #FixTR RTHahnMD Paul Nadira Hamid Univ.-Prof. Dr. Ralph Stephan von Bardeleben Philipp Lurz Abbott Cardiovascular DoctorKini Sahil Khera Lucy Parasuram Krishnamoorthy MD abbott.mediaroom.com/2024-04-02-Abb…

FIH SESAME data now out in #JACC: bit.ly/4c98Uo3 Transcatheter myotomy for oHCM and pre-TMVR Adam Greenbaum Vasilis Babaliaros @TheBethesdaLabs Jamie McCabe

My conclusion is: TAVI (whoppingly) superior to SAVR at 1 year in this trial where the heart team decided on type of transcatheter heart valve for their patient. David J. Cohen, MD, MSc Univ.-Prof. Dr. Ralph Stephan von Bardeleben @MattiAdam_MD Philipp Lurz

Dr. Kearney and I discuss the Short Cut Trial and how it moves the needle from "My best guess" to "here is the best data in real world practice" as this trial evaluates multiple modalities for calcium treatment. #shortcuttrial @kalaswadMD Margaret McEntegart @cardiofrizz Robert Stoler MD

📣 Exciting collaboration alert! #JACC & The Lancet align to enhance their joint impact on cardiovascular health to better serve patients, readers, and society. bit.ly/3Ux0oHv #Cardiology #GlobalHealth #CVResearch Harlan Krumholz richard horton

The Sideclose technique for #Impella access site bleeding new in MyJSCAI. Stop the bleeding, keep the Impella! @jason_wollmuth #MCS doi.org/10.1016/j.jsca…

An amazing electrosurgery workshop led by Jaffar Khan and OPCI yesterday. The future of this innovative field is exciting and bright.

An incredible weekend OPCI with thought leaders and innovators in the field, set in a unique format that encouraged discussion and debate. Nothing quite like it. Thank you again to the organizers. #OPCI24

I'm always blown away at the innovative ways in which our colleagues treat patients. Thank you CV Innovations and the organizers for having me in Denver! #CVI2024

Edwards Lifesciences buys JenaValve. Four acquisitions in a week finance.yahoo.com/news/edwards-l…

A high percentage of patients are unable to undergo a valve-in-valve TAVI procedure due to the high associated risks of sinus sequestration, coronary occlusion, or prevention of future coronary reaccess. The Splitter device, currently under testing, performs leaflet modification

My main takeaway from RHEIA: The first ever RCT only including women sets the scene for TAVI being the default strategy in female<75 with severe AS🔥🔥! Better access, short hospital stay, faster recovery + excellent clinical and echo outcomes.

EARLY-TAVR at #TCT2024 showed significant benefit of TAVR in asymptomatic patients with severe AS. Presented by Philippe Genereux 👉🏻Asymptomatic patients w/ negative stress test enrolled 👉🏻Median f/u ~4 years 👉🏻Primary endpoint death, stroke, unplanned CV hosp, 50% lower eith TAVR

#TCT2024 #LBCT #EarlyTAVR Philippe Genereux Patients w asymptomatic, severe AS, a strategy of early TAVR compared w clinical surveillance: Resulted in a significant reduction of the PEP: death, stroke, or unplanned CV hospitalization Multiple endpoint variations demonstrated

🚨🚨CALL FOR SUBMISSIONS🚨🚨 The journal has introduced a new section, Applied Clinical Evidence. We encourage you to submit a clinical vignette and engage with your readers in real time, benefitting the cardiology community at large. More info below: sciencedirect.com/journal/the-am…

🚨🚨CALL FOR SUBMISSIONS🚨🚨 The American Journal of Cardiology presents our new Applied Clinical Evidence section: an interactive, engaging & informative way to put evidence into practice! sciencedirect.com/journal/the-am… JM Schussler, MD Nadira Hamid Robert Stoler MD Giuseppe_Tarantini Wally A. Omar, MD

Had an amazing time at the OPCI structural complications course, learning how tips and tricks to get out of some seriously sticky situations. Thank you to Jamie McCabe Dr. Bill Lombardi Jaffar Khan Jason Foerst Rhian E. Davies DO MS Jeremy Rier Christine Chung

🔥TELLTALE LBCT results🔥 90 patients at risk of TAVR coronary obstruction enrolled. Primary Endpoints: Efficacy: 100% Safety: 96% Wow! NIH NHLBI St. Francis Hospital & Heart Center Azeem Latib Jason Foerst Jamie McCabe David J. Cohen, MD, MSc Jeremy Rier Adam Greenbaum CRT Meeting

sciencedirect.com/science/articl… Cōngratulatiōns tō David Elison, Richard Sheu, Christine Chung, and the team UWStructualHeart ōn their publicatiōn detailing the use ōf ŌNŌ to remōve a bullet frōm the heart. Amazing wōrk. ŌNŌ helps again….